New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients: Basel Friday, September 20, 2024, 12:00 Hrs [IST] Novartis announced new data ...
Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.
The Outsourcing in Clinical Trials New England conference will gather pharma experts to discuss the current clinical trial ...